Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Adenovirus type 4 vaccine, live + adenovirus type 7 vaccine, live is an **oral live biologic vaccine** for active immunization against febrile acute respiratory disease caused by **adenovirus serotypes 4 and 7**. It was originally developed and manufactured by **Barr** and later approved in the United States in 2011, with current marketing by **Teva**. The product is formulated as **two enteric-coated tablets**, one containing live adenovirus type 4 and one containing live adenovirus type 7, which are swallowed whole. The vaccine replicates in the **intestinal tract** rather than the respiratory tract, inducing protective immunity that helps prevent disease from wild-type adenovirus 4 and 7. It is specifically approved for **military personnel aged 17 through 50 years**, particularly recruits in basic training, and vaccinated individuals may shed live vaccine virus in stool for up to 28 days after administration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on adenovirus type 4 vaccine, live + adenovirus type 7 vaccine, live.